Simplified Chinese
scroll down
14
2025-08
On July 31, Beijing Minhai Biotechnology Co., Ltd. successfully held an “Innovative Vaccine Technology Seminar” in the First Conference Room of its R&D Building, focusing on cutting-edge research into therapeutic vaccines for myasthenia gravis (MG). The event was attended by the company’s Executive Deputy General Manager, expert advisors, deputy general managers, production leaders, the general manager’s assistant, and more than 60 key R&D personnel. Professor Roger from the George Washington University School of Medicine was invited to deliver the keynote address, sharing the latest research findings and technological breakthroughs in this field. Professor Roger has devoted over thirty years to studying the pathogenesis and treatment of myasthenia gravis. He explained that MG is an antibody‑mediated autoimmune disorder whose core mechanism involves the immune system mistakenly attacking acetylcholine receptors at the neuromuscular junction, thereby blocking nerve signal transmission and causing muscle weakness. Currently, clinical management primarily relies on immunosuppressants and targeted antibodies; while these approaches can alleviate symptoms, they are associated with significant long-term side effects, high costs, and the inability to achieve a cure. In response to this unmet clinical need, Professor Roger’s team has innovatively developed a therapeutic vaccine based on proteins within the intramembrane region of the acetylcholine receptor. Animal studies have demonstrated that this vaccine can elicit a specific antibody response, delivering “threefold therapeutic benefits”: redirecting the antibody response from the extracellular domain to the intramembrane region, thus reducing the pathogenic antibodies’ attack on the neuromuscular junction; markedly diminishing antibody‑induced activation of the complement system, thereby mitigating immune‑mediated tissue damage; and inducing a shift in antibody subtypes, converting highly pathogenic IgG2b into non‑pathogenic variants. In rat models, after administration at an optimized dose, MG symptoms were completely suppressed, with protective effects sustained for six months following discontinuation of treatment and no apparent adverse effects—offering a novel approach toward curing MG. As a leading biopharmaceutical enterprise in China, Minhai Biotechnology has consistently placed “unmet clinical needs” at the heart of its R&D strategy. This seminar not only showcased the company’s forward‑looking initiatives in the vaccine field but also established a high‑level academic platform for advancing therapies for neuroimmune disorders. Looking ahead, Minhai Biotechnology will continue to ramp up R&D investment, accelerating the translation of innovative treatments from the laboratory into clinical practice, and contributing Chinese expertise to patients worldwide. Views: 910 Modified on August 5, 2025
04
2025-07
Recently, the People’s Government of Beijing Municipality issued a decision on the 2024 Beijing Science and Technology Awards. In this year’s selection, the project “Research and Industrialization of a Novel Pneumococcal Vaccine Series,” led by Beijing Minhai Biotechnology Co., Ltd. and jointly undertaken with the National Institute for Food and Drug Control, Jiangnan University, and the Jiangsu Provincial Center for Disease Control and Prevention, was awarded the Second Prize in the Science and Technology Progress category. This honor represents high recognition of the company’s groundbreaking technological innovations and their successful translation into practical applications in the biopharmaceutical field. The project aligns with the national and municipal strategic priorities for developing cutting-edge, high‑tech industries and has pioneered the establishment of a high‑value pneumococcal…
02
2025-07
Recently, Minhai Biologics’ 13-valent pneumococcal polysaccharide conjugate vaccine has obtained a GMP certification issued by the Turkish Medicines and Medical Devices Agency. This certification confirms that the company’s PCV13 production facilities, processes, quality control systems, and overall quality management framework all comply with Turkey’s stringent pharmaceutical manufacturing quality standards, thereby establishing that the product meets the necessary requirements for market access in Turkey. As a “crossroads” connecting Europe and Asia, Turkey enjoys a distinct geographical advantage. The country’s economy is growing rapidly, with its GDP ranking among the top 20 globally. In 2024, Turkey’s total population was approximately 8…
02
2025-07
Recently, the 23rd CPHI China—the world’s leading pharmaceutical ingredients exhibition—was grandly held at the Shanghai New International Expo Center, bringing together the global pharmaceutical industry’s leading players and forging deep connections with international markets and premium resources. Beijing Minhai Biotechnology Co., Ltd., together with its parent company Kintor Pharmaceutical, once again showcased its groundbreaking products at this prestigious event, including the world’s first “dual‑carrier” 13‑valent pneumococcal polysaccharide conjugate vaccine and the globally exclusive 60‑microgram hepatitis B vaccine, while engaging with partners to discuss cutting‑edge industry trends and explore potential collaboration opportunities. During the exhibition, Kintor Minhai highlighted its diverse product portfolio and extensive R&D capabilities on site.
24
2025-06
The summer sun blazes, and waves of heat sweep across the landscape. To effectively ensure heat‑related safety and cooling measures during periods of extreme temperatures, mitigate potential health and safety risks to employees, and safeguard their rights to safety and well‑being, on the morning of June 18, 2025, Cao Zijian, Deputy Secretary of the Party Working Committee and Chairman of the Trade Union at the Daxing Biomedical Base, led union staff—bearing heartfelt concern and warm greetings—to Minhai Biotechnology Co., Ltd. They presented frontline workers who remain on duty despite the sweltering heat with care packages containing practical heat‑relief items such as watermelon and Lianhua Qingwen herbal remedies, bringing a touch of coolness and comfort to the scorching summer days. During the visit, Secretary Cao warmly…
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%